Modest Phenotypic Improvements in ASA-deficient Mice with Only One UDP-galactose:ceramide-galactosyltransferase Gene

Overview

Journal Lipids Health Dis

Publisher Biomed Central

Specialties Biochemistry
Endocrinology

Date 2006 Aug 9

PMID 16893448

Authors

S Franken

D Wittke

J E Mansson

R DHooge

P P De Deyn

R Lullmann-Rauch

U Matzner

V Gieselmann

Affiliations

Soon will be listed here.

Abstract

Background: Arylsulfatase A (ASA)-deficient mice are a model for the lysosomal storage disorder metachromatic leukodystrophy. This lipidosis is characterised by the lysosomal accumulation of the sphingolipid sulfatide. Storage of this lipid is associated with progressive demyelination. We have mated ASA-deficient mice with mice heterozygous for a non-functional allele of UDP-galactose:ceramide-galactosyltransferase (CGT). This deficiency is known to lead to a decreased synthesis of galactosylceramide and sulfatide, which should reduce sulfatide storage and improve pathology in ASA-deficient mice.

Results: ASA-/- CGT+/- mice, however, showed no detectable decrease in sulfatide storage. Neuronal degeneration of cells in the spiral ganglion of the inner ear, however, was decreased. Behavioural tests showed small but clear improvements of the phenotype in ASA-/- CGT+/- mice.

Conclusion: Thus the reduction of galactosylceramide and sulfatide biosynthesis by genetic means overall causes modest improvements of pathology.

References

DHooge R, Coenen R, Gieselmann V, Lullmann-Rauch R, De Deyn P . Decline in brainstem auditory-evoked potentials coincides with loss of spiral ganglion cells in arylsulfatase A-deficient mice. Brain Res. 1999; 847(2):352-6. DOI: 10.1016/s0006-8993(99)02085-5. View

Sands M, Davidson B . Gene therapy for lysosomal storage diseases. Mol Ther. 2006; 13(5):839-49. DOI: 10.1016/j.ymthe.2006.01.006. View

Ezoe T, Vanier M, Oya Y, Popko B, Tohyama J, Matsuda J . Twitcher mice with only a single active galactosylceramide synthase gene exhibit clearly detectable but therapeutically minor phenotypic improvements. J Neurosci Res. 2000; 59(2):179-87. DOI: 10.1002/(sici)1097-4547(20000115)59:2<179::aid-jnr4>3.0.co;2-n. View

Jeyakumar M, Norflus F, Tifft C, Cortina-Borja M, Butters T, Proia R . Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation. Blood. 2001; 97(1):327-9. DOI: 10.1182/blood.v97.1.327. View

DHooge R, van Dam D, Franck F, Gieselmann V, De Deyn P . Hyperactivity, neuromotor defects, and impaired learning and memory in a mouse model for metachromatic leukodystrophy. Brain Res. 2001; 907(1-2):35-43. DOI: 10.1016/s0006-8993(01)02374-5. View

Coenen R, Gieselmann V, Lullmann-Rauch R . Morphological alterations in the inner ear of the arylsulfatase A-deficient mouse. Acta Neuropathol. 2001; 101(5):491-8. DOI: 10.1007/s004010000318. View

Schott I, Hartmann D, Gieselmann V, Lullmann-Rauch R . Sulfatide storage in visceral organs of arylsulfatase A-deficient mice. Virchows Arch. 2001; 439(1):90-6. DOI: 10.1007/s004280000360. View

Lullmann-Rauch R, Matzner U, Franken S, Hartmann D, Gieselmann V . Lysosomal sulfoglycolipid storage in the kidneys of mice deficient for arylsulfatase A (ASA) and of double-knockout mice deficient for ASA and galactosylceramide synthase. Histochem Cell Biol. 2001; 116(2):161-9. DOI: 10.1007/s004180100286. View

Siatskas C, Medin J . Gene therapy for Fabry disease. J Inherit Metab Dis. 2002; 24 Suppl 2:25-41; discussion 11-2. DOI: 10.1023/a:1012455421014. View

10.

Matzner U, Hartmann D, Lullmann-Rauch R, Coenen R, ROTHERT F, Mansson J . Bone marrow stem cell-based gene transfer in a mouse model for metachromatic leukodystrophy: effects on visceral and nervous system disease manifestations. Gene Ther. 2002; 9(1):53-63. DOI: 10.1038/sj.gt.3301593. View

11.

Pastores G, Thadhani R . Advances in the management of Anderson-Fabry disease: enzyme replacement therapy. Expert Opin Biol Ther. 2002; 2(3):325-33. DOI: 10.1517/14712598.2.3.325. View

12.

Schiffmann R, Brady R . New prospects for the treatment of lysosomal storage diseases. Drugs. 2002; 62(5):733-42. DOI: 10.2165/00003495-200262050-00002. View

13.

Moyses C . Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease. Philos Trans R Soc Lond B Biol Sci. 2003; 358(1433):955-60. PMC: 1693174. DOI: 10.1098/rstb.2003.1271. View

14.

Butters T, Dwek R, Platt F . New therapeutics for the treatment of glycosphingolipid lysosomal storage diseases. Adv Exp Med Biol. 2004; 535:219-26. DOI: 10.1007/978-1-4615-0065-0_14. View

15.

Ellinwood N, Vite C, Haskins M . Gene therapy for lysosomal storage diseases: the lessons and promise of animal models. J Gene Med. 2004; 6(5):481-506. DOI: 10.1002/jgm.581. View

16.

Eto Y, Shen J, Meng X, Ohashi T . Treatment of lysosomal storage disorders: cell therapy and gene therapy. J Inherit Metab Dis. 2004; 27(3):411-5. DOI: 10.1023/B:BOLI.0000031170.69676.68. View

17.

Vaughan C, Gotto Jr A . Update on statins: 2003. Circulation. 2004; 110(7):886-92. DOI: 10.1161/01.CIR.0000139312.10076.BA. View

18.

Elstein D, Hollak C, Aerts J, Van Weely S, Maas M, Cox T . Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J Inherit Metab Dis. 2004; 27(6):757-66. DOI: 10.1023/B:BOLI.0000045756.54006.17. View

19.

BAIRD I, WINBORN W, Bockman D . A technique of decalcification suited to electron microscopy of tissues closely associated with bone. Anat Rec. 1967; 159(3):281-9. DOI: 10.1002/ar.1091590306. View

20.

Svennerholm L, Fredman P . A procedure for the quantitative isolation of brain gangliosides. Biochim Biophys Acta. 1980; 617(1):97-109. DOI: 10.1016/0005-2760(80)90227-1. View